Humulin M3 (30/70) Kwikpen (Insulin Human)

Humulin M3 (30/70) Kwikpen is indicated for the treatment of diabetes mellitus in adults and children who require a combination of rapid‑acting and intermediate‑acting insulin.

• Control of fasting and post‑prandial blood glucose in Type 1 diabetes.
• Control of fasting and post‑prandial blood glucose in Type 2 diabetes.
• Basal‑bolus insulin regimens where a premixed insulin simplifies dosing.
• Patients who prefer a pre‑filled pen device for ease of administration.
• Adjunct to diet and exercise in patients unable to achieve targets with oral agents alone.

• Humulin M3 (30/70) contains human insulin that binds to the insulin receptor on cell membranes, activating the intrinsic tyrosine kinase activity of the receptor. This triggers downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and enhancing glucose uptake in muscle and adipose tissue, while inhibiting hepatic gluconeogenesis. The soluble fraction acts within 30 minutes, and the NPH fraction provides a prolonged effect lasting up to 24 hours.

Adverse reactions to Humulin M3 (30/70) Kwikpen are reported in clinical use and may vary in frequency and severity.

Common

• Hypoglycemia, especially if meals are missed or activity is increased.
• Injection‑site pain, redness, or swelling.
• Lipodystrophy or lipoatrophy at the injection site.
• Weight gain associated with improved glycemic control.
• Mild allergic skin reactions such as rash or urticaria.

Serious

• Severe hypoglycemia requiring assistance.
• Anaphylactic reaction or angioedema.
• Hypokalemia due to rapid intracellular shift of potassium.
• Diabetic ketoacidosis if insulin therapy is abruptly discontinued.
• Acute insulin allergy with systemic symptoms.

When prescribing or using Humulin M3 (30/70) Kwikpen, clinicians should consider several safety considerations to reduce risk.

• Monitor closely for hypoglycemia, especially during dose adjustments or changes in diet.
• Adjust doses in patients with renal or hepatic impairment.
• Use with caution during pregnancy and lactation; evaluate benefit‑risk balance.
• Observe for signs of allergic reactions, particularly in patients with known insulin sensitivities.
• Avoid use in individuals with documented hypersensitivity to human insulin or any excipients.
• Assess cardiovascular status, as insulin may influence fluid retention and blood pressure.

Humulin M3 (30/70) can interact with other medicines, altering glucose control or increasing adverse event risk.

Avoid

• Concurrent use of additional insulin products without appropriate dose reduction.
• Beta‑blockers that may mask hypoglycemia symptoms.
• Monoamine oxidase inhibitors, which can potentiate insulin‑induced hypoglycemia.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycemia risk.
• Corticosteroids, thiazide diuretics, and sympathomimetic drugs that may raise blood glucose, requiring dose adjustments.
• Alcohol consumption, which can enhance insulin’s glucose‑lowering effect.